Human neutrophil antigen 3 genotype impacts neutrophil-mediated endothelial cell cytotoxicity in a two-event model of TRALI.
Journal
Blood transfusion = Trasfusione del sangue
ISSN: 2385-2070
Titre abrégé: Blood Transfus
Pays: Italy
ID NLM: 101237479
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
13
01
2022
accepted:
08
04
2022
pubmed:
19
7
2022
medline:
15
12
2022
entrez:
18
7
2022
Statut:
ppublish
Résumé
Antibodies against human neutrophil antigen (HNA)-3a are associated with severe cases of transfusion-related acute lung injury (TRALI). The HNA-3 system is located on choline transporter-like 2 (CTL-2) protein. CTL-2 is encoded by the gene SLC44A2 and a single-nucleotide polymorphism c.461G>A results in two antigens: HNA-3a and HNA-3b. Three HNA-3 genotypes/ phenotypes exist: HNA-3aa, HNA-3bb, and HNA-3ab. Two different pathways of anti-HNA-3a TRALI have been described: a two-hit neutrophil-dependent pathway and a one-hit neutrophil-independent pathway. However, it is not clear whether HNA-3ab heterozygous patients have a lower risk of anti-HNA-3a-mediated TRALI compared to HNA-3aa homozygous patients. Healthy volunteers were genotyped for HNA-3 by real-time polymerase chain reaction, and phenotyped for HNA-3a by granulocyte immunofluorescence test (GIFT) and granulocyte agglutination test (GAT) against two donor sera containing anti-HNA-3a antibodies. The two sera were also used in in vitro models of human pulmonary microvascular endothelial cell (HLMVEC) cytotoxicity to investigate pathways of TRALI development. For both anti-HNA-3a sera, GIFT results matched the genotype, with a lower GIFT ratio for HNA-3ab neutrophils compared to HNA-3aa neutrophils, whereas GAT results showed no difference in agglutination. HLMVEC cytotoxicity was not observed in a one-hit neutrophil-independent model but was observed in a two-hit neutrophil-dependent model. Differences in cytotoxicity were observed between the two anti-HNA-3a sera used. Consistent with reduced HNA-3a antigen density as measured by GIFT, HNA-3ab neutrophils mediated less HLMVEC cytotoxicity than HNA-3aa neutrophils. HNA-3 genotype and HNA-3a antigen expression impacted the severity of anti-HNA-3a-mediated HLMVEC cytotoxicity in a two-hit neutrophil-dependent model of TRALI. Different HNA-3a antibodies might also impact the magnitude of HLMVEC cytotoxicity.
Sections du résumé
BACKGROUND
Antibodies against human neutrophil antigen (HNA)-3a are associated with severe cases of transfusion-related acute lung injury (TRALI). The HNA-3 system is located on choline transporter-like 2 (CTL-2) protein. CTL-2 is encoded by the gene SLC44A2 and a single-nucleotide polymorphism c.461G>A results in two antigens: HNA-3a and HNA-3b. Three HNA-3 genotypes/ phenotypes exist: HNA-3aa, HNA-3bb, and HNA-3ab. Two different pathways of anti-HNA-3a TRALI have been described: a two-hit neutrophil-dependent pathway and a one-hit neutrophil-independent pathway. However, it is not clear whether HNA-3ab heterozygous patients have a lower risk of anti-HNA-3a-mediated TRALI compared to HNA-3aa homozygous patients.
MATERIALS AND METHODS
Healthy volunteers were genotyped for HNA-3 by real-time polymerase chain reaction, and phenotyped for HNA-3a by granulocyte immunofluorescence test (GIFT) and granulocyte agglutination test (GAT) against two donor sera containing anti-HNA-3a antibodies. The two sera were also used in in vitro models of human pulmonary microvascular endothelial cell (HLMVEC) cytotoxicity to investigate pathways of TRALI development.
RESULTS
For both anti-HNA-3a sera, GIFT results matched the genotype, with a lower GIFT ratio for HNA-3ab neutrophils compared to HNA-3aa neutrophils, whereas GAT results showed no difference in agglutination. HLMVEC cytotoxicity was not observed in a one-hit neutrophil-independent model but was observed in a two-hit neutrophil-dependent model. Differences in cytotoxicity were observed between the two anti-HNA-3a sera used. Consistent with reduced HNA-3a antigen density as measured by GIFT, HNA-3ab neutrophils mediated less HLMVEC cytotoxicity than HNA-3aa neutrophils.
CONCLUSION
HNA-3 genotype and HNA-3a antigen expression impacted the severity of anti-HNA-3a-mediated HLMVEC cytotoxicity in a two-hit neutrophil-dependent model of TRALI. Different HNA-3a antibodies might also impact the magnitude of HLMVEC cytotoxicity.
Identifiants
pubmed: 35848624
pii: 2022.0013-22
doi: 10.2450/2022.0013-22
pmc: PMC9726621
doi:
Substances chimiques
Isoantigens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
465-474Références
Blood Rev. 2022 May;53:100926
pubmed: 35065815
Nat Med. 2010 Jan;16(1):45-8
pubmed: 20037594
Am Rev Respir Dis. 1983 Jul;128(1):185-9
pubmed: 6603182
Blood. 2006 Oct 1;108(7):2455-62
pubmed: 16772606
Int J Immunogenet. 2021 Apr;48(2):145-156
pubmed: 32970372
Transfusion. 2014 Dec;54(12):3208-15
pubmed: 24846273
Transfusion. 2011 Jun;51(6):1271-7
pubmed: 21166683
Curr Opin Hematol. 2011 Nov;18(6):452-60
pubmed: 21912255
Transfus Med Hemother. 2018 Oct;45(5):300-309
pubmed: 30498408
Transfusion. 2011 Apr;51(4):820-7
pubmed: 20977484
Vox Sang. 1986;51(2):102-7
pubmed: 3095987
Transfusion. 2011 Jan;51(1):18-24
pubmed: 20561293
Blood. 1993 Aug 15;82(4):1097-106
pubmed: 7688987
Transfusion. 2015 Jun;55(6 Pt 2):1512-21
pubmed: 25385443
Arterioscler Thromb Vasc Biol. 2013 Nov;33(11):2538-48
pubmed: 24008160
Blood. 2007 Feb 15;109(4):1752-5
pubmed: 17038531
Vox Sang. 2011 Nov;101(4):282-90
pubmed: 21933191
Vox Sang. 2008 Nov;95(4):313-7
pubmed: 19138261
JAMA. 2002 Apr 17;287(15):1968-71
pubmed: 11960539
Mayo Clin Proc. 1985 May;60(5):312-4
pubmed: 3990379
Crit Care Med. 2006 May;34(5 Suppl):S124-31
pubmed: 16617256
Transfusion. 2012 May;52(5):1106-11
pubmed: 22040064
Transfusion. 2002 Apr;42(4):462-8
pubmed: 12076294
Vox Sang. 2014 Jul;107(1):76-82
pubmed: 24372341
Am J Physiol Cell Physiol. 2002 Dec;283(6):C1592-603
pubmed: 12388071